Clinical trial
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
NCT00071409 · Exsulin Corporation, Industry · Completed
Key facts
| NCT number | NCT00071409 |
|---|---|
| Title | Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes |
| Official title | A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients |
| Lead sponsor | Exsulin Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Insulin-Dependent |
| Intervention type | Drug |
| Interventions | INGAP-Peptide, placebo |
| Enrollment | 63 |
| Start date | Oct 1, 2003 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Oct 23, 2003 |
| Last update posted | Jul 11, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: